demonstrate that a leaky blood–brain tumor barrier may remain an impediment to effective pharmacotherapy of melanoma brain metastases, by showing that ABC transporters restrict vemurafenib drug delivery and efficacy against BRAFV600‐driven melanoma brain metastases even when barrier integrity is compromised. Here, ABCG2 is linked to brain neoplasm.